This meeting gathered all MIROCALS partners for presenting the progress made since the launch of the project a year ago as well as the next achievements for the coming year.
The MIROCALS consortium is delighted to announce that the first participant has been recruited to the MIROCALS trial, at Hospices Civils de Lyon, France.
Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases such as ALS and their impact on patients' lives.
Take a look at the events happening around the world for rare disease day: https://www.rarediseaseday.org/
Results in this paper reveal that low dose IL-2 significantly increased the numbers of circulating Tregs, as predicted, and – importantly – improved their ability to control other immune cell responses that contribute to nerve cell damage.
Further information can be found at MND Research Blog
The MIROCALS (Modifying Immune Response and Outcomes in ALS) Clinical Trial is still on-going, with recruitment continuing until the end of September 2019.
Read more
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.